CW June 2005
Volume 14Issue Number 6 June 2005 ISSN 10593802 Adjuvant Trastuzumab Can Reduce Breast Cancer Recurrence in HER2+ PatientsThe addition of the targeted therapy trastuzumab (Herceptin) as adjuvant treatment of women with early human epidermal growth factor receptor-2 positive breast cancer produces a major reduction in risk recurrence at least as large as the effect of tamoxifen in estrogen-receptor (ER) positive tumors.
Go to Previous Page Go to Next Page Source & Additional Reading Report from the American Society of Clinical Oncology, Purchase Downloadable Full-text PDF of Article: $10.00 Subscription is more cost effective than purchasing PDFs on-the-fly. Click here for details. Download Complete Issue CW June 2005Purchase Downloadable Full-text PDF of Complete Issue: $20.00 |
|
Member Login | Home | Offices | Subscribe | Glossary | Cancer Technologies | Contact Us
Adenine Press, 2066 Central Avenue, Schenectady, NY 12304 USA |
Re-initialize IP-based Login |
